Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Nutritional-GINot yet recruiting Location: QLD Australia
The effect of withdrawal of oral iron supplementation on airway microbiology and outcomes in cystic fibrosis. , protocol number ACTRN12612000146897
An open-label study to examine the effects of withdrawal of oral iron supplements on airway iron content and microbiology in patients with CF.
Age:
18 -70 Years
Mutation(s):
Not specified
FEV1% Predicted:
Not Specified
Number of Visits:
Length of Participation:
OtherEnrolling Location: NSW AUSTRALIA
Prevalence of hypoglycaemia and the role of incretins and glucagon during extended oral glucose tolerance test in people with Cystic Fibrosis. , protocol number ACTRN12616001175460
This study aims to identify the prevalence of hypoglycaemia during extended OGTT's and associations with biochemical parameters relevant to glucose metabolism. In particular, this study will explore the role of glucagon and the incretions GLP-1 and GIP in reactive hypoglycaemia during OGT's.
18-45 Years
0
OtherEnrolling Location: NSW - Australia
Is inhaled tobramycin as effective as intravenous tobramycin and potentially less toxic for treating acute exacerbations of lung infection in those patients with cystic fibrosis (CF) who are chronically colonised with Pseudomonas aeruginosa? , protocol number ACTRN12609000016235
This study hopes to show that when tobramycin is given via inhalation in those cystic fibrosis patients sick enough to need intravenous (into a vein) antibiotics, the levels in the lung are adequate for effective bacteria elimination and they recover from acute infection. The study will be undertaken in all eligible patients admitted to hospital for treatment of an exacerbation of their lung infection.
6 Years and older
An International, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Mixture Formulation Consisting of Liposomal and Free Ciprofloxacin for inhalation Compared with Placebo for inhalation in the Management of Pseudomonas aeruginosa in Patients with Non-Cystic Fibrosis Bronchiectasis with Chronic Lung infections. , protocol number NCT01515007 ACTRN12609000578202
This study will compare the safety and efficacy of the mixture formulation consisting of liposomal and free ciprofloxacin for inhalation to placebo for inhalation in patients who have confirmed diagnosis of non-CF bronchiectasis with a history of chronic Pseudomonas Aeruginosa infections.
18 Years to 80 Years
A phase 1/11 randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy inhalation in patients with cystic fibrosis (CF). , protocol number ACTRN12610000328077
The clinical trial is to assess the safety and tolerability and to explore the efficacy of orally inhaled heparin in patients with cystic fibrosis (CF). Heparin is expected to provide advantages over currently available treatments for CF in a convenient delivery system.
16 Years
OtherEnrolling Location: Australia
Children and adolescents with cystic fibrosis attending the Women's and Children's Hospital Ambulatory Cystic Fibrosis Physiotherapy Clinic - effect on quality of life, number of occupied bed days, pulmonary function and exercise capacity. , protocol number ACTRN12611000160932
To determine the effect of participation in the Ambulatory CF Physiotherapy on patients quality of life, lung function, fitness and number of days in hospital.
0 to 18 Years
OtherRecruiting Location: NSW - Australia
Randomised trial of the effect of nebulised hypertonic saline in relation to airways clearance physiotherapy, on subjective efficacy, tolerability and overall satisfaction, and lung function parameters in adults with cystic fibrosis lung disease. , protocol number ACTRN12611000673943
Research question: To determine whether the timing of HS inhalation (before, during or after airway clearance physiotherapy) impacts the subjective efficacy, tolerability and overall satisfaction, of lung function parameters in adults with cystic fibrosis.
18 Years and Older
Vaccine compared to quadrivalent (ACYW135) meningococcal conjuate vaccine in reducing respiratory exacerbations in children aged greater then or equal to 18 months with suppurative lung disease. , protocol number ACTRN12612000034831
Chronic suppurative lung diseases in children are major causes of morbidity and mortality worldwide, particularly in disadvantaged populations. Repeated infections in childhood contribute to poor lung health in adulthood. The most common organism associated with infection is non-typeable Haemophilus influenzae (NTHi). This study aims to determine whether a vaccine against NTHi (10v-PHiD) can reduce repeated respiratory infections in children. We will be comparing the number of respiratory exacerbation's in the 12 months following vaccinated children with chronic lung disease vaccinated with 10vPHiD and children who received a meningococcal vaccine (control vaccine).
18 Months to 15 Years
The effect of azithromycin and hypertonic saline on quality of life, lung function and exercise capacity in adults with non-cystic fibrosis bronchiectasis. , protocol number ACTRN12611001199909
The purpose of this study is to access the efficacy of an oral antibiotic (Azithromycin) and an inhaled mucus-clearance agent (nebulised salt water known as hypertonic saline) in people with bronchiectasis that is not due to cystic fibrosis. The interventions will be administered over a 6 month period. The investigators hypothesise that each intervention will improve the quality of the people with bronchiectasis by reducing the severity of the chronic lung infection.
OtherEnrolling Location: NSW, QLD, SA & VIC - Australia
A randomised controlled trial of effects of early life exposure to general anaesthesia on neurobehavioural outcomes in children with cystic fibrosis (CF) , protocol number ACTRN12613000057785
The use of general anaesthesia (GA) in infants and young children has generally been considered safe. Recent research from laboratory animal studies has raised concerns that exposure to anaesthetic medicines in early life could potentially be related to impaired memory, learning and behaviour. This study takes advantage of the previous randomisation in the ACFBAL study (ACTRN 12605000665639)
9 Years to 15 Years